Annual EBITDA
-$15.23 M
+$12.25 M+44.58%
December 31, 2023
Summary
- As of February 8, 2025, ALRN annual EBITDA is -$15.23 million, with the most recent change of +$12.25 million (+44.58%) on December 31, 2023.
- During the last 3 years, ALRN annual EBITDA has risen by +$5.10 million (+25.10%).
- ALRN annual EBITDA is now -21.19% below its all-time high of -$12.57 million, reached on December 31, 2015.
Performance
ALRN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$6.07 M
+$2.96 M+32.81%
September 30, 2024
Summary
- As of February 8, 2025, ALRN quarterly EBITDA is -$6.07 million, with the most recent change of +$2.96 million (+32.81%) on September 30, 2024.
- Over the past year, ALRN quarterly EBITDA has dropped by -$4.11 million (-208.96%).
- ALRN quarterly EBITDA is now -208.96% below its all-time high of -$1.97 million, reached on September 30, 2023.
Performance
ALRN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$29.50 M
-$4.11 M-16.17%
September 30, 2024
Summary
- As of February 8, 2025, ALRN TTM EBITDA is -$29.50 million, with the most recent change of -$4.11 million (-16.17%) on September 30, 2024.
- Over the past year, ALRN TTM EBITDA has dropped by -$16.86 million (-133.42%).
- ALRN TTM EBITDA is now -661.93% below its all-time high of -$3.87 million, reached on March 31, 2016.
Performance
ALRN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALRN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +44.6% | -209.0% | -133.4% |
| 3 y3 years | +25.1% | -30.3% | -7.4% |
| 5 y5 years | +51.9% | -30.3% | -7.4% |
ALRN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +44.6% | -209.0% | +32.8% | -133.4% | +1.4% |
| 5 y | 5-year | at high | +48.9% | -209.0% | +32.8% | -133.4% | +1.4% |
| alltime | all time | -21.2% | +51.9% | -209.0% | +36.9% | -661.9% | +7.1% |
Aileron Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$6.07 M(-32.8%) | -$29.50 M(+16.2%) |
| Jun 2024 | - | -$9.04 M(+26.4%) | -$25.40 M(+37.8%) |
| Mar 2024 | - | -$7.15 M(-1.4%) | -$18.43 M(+21.0%) |
| Dec 2023 | -$15.23 M(-44.6%) | -$7.25 M(+269.0%) | -$15.23 M(+20.5%) |
| Sep 2023 | - | -$1.97 M(-5.0%) | -$12.64 M(-26.1%) |
| Jun 2023 | - | -$2.07 M(-47.6%) | -$17.11 M(-25.7%) |
| Mar 2023 | - | -$3.95 M(-15.3%) | -$23.04 M(-16.1%) |
| Dec 2022 | -$27.48 M(+3.8%) | -$4.66 M(-27.6%) | -$27.48 M(-7.2%) |
| Sep 2022 | - | -$6.44 M(-19.5%) | -$29.59 M(-1.0%) |
| Jun 2022 | - | -$8.00 M(-4.5%) | -$29.91 M(+7.3%) |
| Mar 2022 | - | -$8.38 M(+23.7%) | -$27.88 M(+5.3%) |
| Dec 2021 | -$26.48 M(+30.3%) | -$6.78 M(+0.4%) | -$26.48 M(+10.9%) |
| Sep 2021 | - | -$6.75 M(+13.1%) | -$23.89 M(+7.8%) |
| Jun 2021 | - | -$5.97 M(-14.6%) | -$22.15 M(+8.0%) |
| Mar 2021 | - | -$6.99 M(+67.1%) | -$20.51 M(+0.9%) |
| Dec 2020 | -$20.33 M | -$4.18 M(-16.6%) | -$20.33 M(-13.2%) |
| Sep 2020 | - | -$5.01 M(+15.8%) | -$23.43 M(-10.9%) |
| Jun 2020 | - | -$4.33 M(-36.4%) | -$26.30 M(-10.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$6.81 M(-6.4%) | -$29.32 M(-1.6%) |
| Dec 2019 | -$29.80 M(-5.9%) | -$7.27 M(-7.8%) | -$29.80 M(+1.2%) |
| Sep 2019 | - | -$7.89 M(+7.4%) | -$29.46 M(+1.7%) |
| Jun 2019 | - | -$7.35 M(+1.0%) | -$28.98 M(-7.3%) |
| Mar 2019 | - | -$7.28 M(+5.0%) | -$31.25 M(-1.4%) |
| Dec 2018 | -$31.68 M(+38.5%) | -$6.93 M(-6.4%) | -$31.68 M(-0.2%) |
| Sep 2018 | - | -$7.41 M(-23.0%) | -$31.75 M(+3.3%) |
| Jun 2018 | - | -$9.62 M(+24.7%) | -$30.72 M(+18.0%) |
| Mar 2018 | - | -$7.72 M(+10.3%) | -$26.03 M(+13.8%) |
| Dec 2017 | -$22.88 M(+27.6%) | -$7.00 M(+9.6%) | -$22.88 M(+12.8%) |
| Sep 2017 | - | -$6.39 M(+29.6%) | -$20.29 M(+12.2%) |
| Jun 2017 | - | -$4.93 M(+7.9%) | -$18.08 M(-3.0%) |
| Mar 2017 | - | -$4.57 M(+3.7%) | -$18.63 M(+3.9%) |
| Dec 2016 | -$17.94 M(+42.7%) | -$4.41 M(+5.6%) | -$17.94 M(+32.6%) |
| Sep 2016 | - | -$4.17 M(-23.9%) | -$13.53 M(+44.6%) |
| Jun 2016 | - | -$5.49 M(+41.7%) | -$9.36 M(+141.7%) |
| Mar 2016 | - | -$3.87 M | -$3.87 M |
| Dec 2015 | -$12.57 M | - | - |
FAQ
- What is Aileron Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Aileron Therapeutics?
- What is Aileron Therapeutics annual EBITDA year-on-year change?
- What is Aileron Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aileron Therapeutics?
- What is Aileron Therapeutics quarterly EBITDA year-on-year change?
- What is Aileron Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Aileron Therapeutics?
- What is Aileron Therapeutics TTM EBITDA year-on-year change?
What is Aileron Therapeutics annual EBITDA?
The current annual EBITDA of ALRN is -$15.23 M
What is the all time high annual EBITDA for Aileron Therapeutics?
Aileron Therapeutics all-time high annual EBITDA is -$12.57 M
What is Aileron Therapeutics annual EBITDA year-on-year change?
Over the past year, ALRN annual EBITDA has changed by +$12.25 M (+44.58%)
What is Aileron Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ALRN is -$6.07 M
What is the all time high quarterly EBITDA for Aileron Therapeutics?
Aileron Therapeutics all-time high quarterly EBITDA is -$1.97 M
What is Aileron Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ALRN quarterly EBITDA has changed by -$4.11 M (-208.96%)
What is Aileron Therapeutics TTM EBITDA?
The current TTM EBITDA of ALRN is -$29.50 M
What is the all time high TTM EBITDA for Aileron Therapeutics?
Aileron Therapeutics all-time high TTM EBITDA is -$3.87 M
What is Aileron Therapeutics TTM EBITDA year-on-year change?
Over the past year, ALRN TTM EBITDA has changed by -$16.86 M (-133.42%)